The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 200-212

  Linton, Anthony ^a,b,c   Vardy, Janette ^b,c   Clarke, Stephen ^c,d   van Zandwijk, Nico ^a,c  

^a Asbestos Diseases Research Institute   (Australia)

^b ANZAC Research Institute   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Asbestos; Epidemiology; Mesothelioma; Occupational disease

Indexed keywords

ASBESTOS; CHRYSOTILE; ESTROGEN RECEPTOR;

ASBESTOSIS; CANCER INCIDENCE; CARCINOGENICITY; CEMENT INDUSTRY; CHILDHOOD CANCER; ENVIRONMENTAL EXPOSURE; GENETIC MARKER; GENETIC RISK; HUMAN; INDUSTRIAL WORKER; LUNG CANCER; MALIGNANT MESOTHELIOMA; MINER; OCCUPATIONAL EXPOSURE; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; REVIEW; SEX DIFFERENCE; SHIPYARD WORKER; SIMIAN VIRUS 40; TEXTILE WORKER;

ANIMALS; ASBESTOS; FEMALE; HUMANS; MALE; MESOTHELIOMA; OCCUPATIONAL EXPOSURE;

EID: 84867845142     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.001     Document Type: Review

References (131)

1. Cugell D.W., Kamp D.W. Asbestos and the pleura: a review. Chest 2004, 125:1103-1117.
2. Murray M. Departmental Committe for Compensation for Industrial Diseases. CND 3495 & 3496 1907, HMSO, London, UK.
3. Van der Schoot H. Asbestosis en pleuragezwellen. Ned Tijdschr Geneeskd 1958, 102:1125.
4. Weiss A. Pleurakrebs bei Lungenasbestose, in vivo morphologisch gesichert. Medizinische 1953, 3:93-94.
5. Tagnon I., Blot W.J., Stroube R.B., et al. Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 1980, 40:3875-3879.
6. Rake C., Gilham C., Hatch J., Darnton A., Hodgson J., Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009, 100:1175-1183.
7. Chapman A., Mulrennan S., Ladd B., Muers M.F. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63:435-439.
8. Gibbs A.R., Jones J.S., Pooley F.D., Griffiths D.M., Wagner J.C. Non-occupational malignant mesotheliomas. IARC Sci Publ 1989, 219-228.
9. Lacourt A., Rolland P., Gramond C., et al. Attributable risk in men in two French case-control studies on mesothelioma and asbestos. Eur J Epidemiol 2010, 25:799-806.
10. Lin R.-T., Takahashi K., Karjalainen A., et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007, 369:844-849.
11. Greenberg M., Davies T.A. Mesothelioma register 1967-68. Br J Ind Med 1974, 31:91-104.
12. Leigh J., Davidson P., Hendrie L., Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002, 41:188-201.
13. Spirtas R., Heineman E.F., Bernstein L., et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994, 51:804-811.
14. Roggli V.L., Sharma A., Butnor K.J., Sporn T., Vollmer R.T. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002, 26:55-65.
15. Selikoff I.J., Hammond E.C., Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980, 46:2736-2740.
16. Rushton L., Bagga S., Bevan R., et al. Occupation and cancer in Britain. Br J Cancer 2010, 102:1428-1437.
17. Mowe G., Gylseth B. Occupational exposure and regional variation of malignant mesothelioma in Norway, 1970-79. Am J Ind Med 1986, 9:323-332.
18. Kishimoto T., Gemba K., Fujimoto N., et al. Clinical study on mesothelioma in Japan: relevance to occupational asbestos exposure. Am J Ind Med 2010, 53:1081-1087.
19. Iwatsubo Y., Pairon J.C., Boutin C., et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998, 148:133-142.
20. Pukkala E., Martinsen J.I., Lynge E., et al. Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol 2009, 48:646-790.
21. McDonald A.D., McDonald J.C. Malignant mesothelioma in North America. Cancer 1980, 46:1650-1666.
22. Ulvestad B., Kjaerheim K., Martinsen J.I., et al. Cancer incidence among workers in the asbestos-cement producing industry in Norway. Scand J Work Environ Health 2002, 28:411-417.
23. Peto J., Doll R., Hermon C., Binns W., Clayton R., Goffe T. Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg 1985, 29:305-355.
24. Harding A.-H., Darnton A.J. Asbestosis and mesothelioma among British asbestos workers (1971-2005). Am J Ind Med 2010, 53:1070-1080.
25. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
26. Burdorf A., Dahhan M., Swuste P. Occupational characteristics of cases with asbestos-related diseases in The Netherlands. Ann Occup Hyg 2003, 47:485-492.
27. Krstev S., Stewart P., Rusiecki J., Blair A. Mortality among shipyard Coast Guard workers: a retrospective cohort study. Occup Environ Med 2007, 64:651-658.
28. Goodman M., Teta M.J., Hessel P.A., et al. Mesothelioma and lung cancer among motor vehicle mechanics: a meta-analysis. Ann Occup Hyg 2004, 48:309-326.
29. Kelsh M.A., Craven V.A., Teta M.J., Mowat F.S., Goodman M. Mesothelioma in vehicle mechanics: is the risk different for Australians?. Occup Med 2007, 57:581-589.
30. Musk A.W., de Klerk N.H., Eccles J.L., et al. Historical perspectives in occupational medicine. Wittenoom, western Australia: a modern industrial disaster. Am J Ind Med 1992, 21:735-747.
31. Berry G., de Klerk N.H., Reid A., et al. Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Environ Med 2004, 61:e14.
32. Safe-Work-Australia Mesothelioma in Australia - incidence 1982 to 2006 - mortality 1997 to 2007 2010.
33. Newhouse M.L., Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med 1965, 22:261-269.
34. Vianna N.J., Polan A.K. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978, 1:1061-1063.
35. Ferrante D., Bertolotti M., Todesco A., Mirabelli D., Terracini B., Magnani C. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect 2007, 115.
36. Browne K. Asbestos-related mesothelioma: epidemiological evidence for asbestos as a promoter. Arch Environ Health 1983, 38:261-266.
37. Magnani C., Dalmasso P., Biggeri A., Ivaldi C., Mirabelli D., Terracini B. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy. Environ Health Perspect 2001, 109:915-919.
38. Kurumatani N., Kumagai S. Mapping the risk of mesothelioma due to neighborhood asbestos exposure. Am J Respir Crit Care Med 2008, 178:624-629.
39. Botha J.L., Irwig L.M., Strebel P.M. Excess mortality from stomach cancer, lung cancer, and asbestosis and/or mesothelioma in crocidolite mining districts in South Africa. Am J Epidemiol 1986, 123:30-40.
40. Sullivan P. Jes Skramstad: Mont. miner exposed asbestos poisoning 2007, The Washington Post, p. B07.
41. Noonan C.W. Exposure matrix development for the Libby cohort. Inhal Toxicol 2006, 18:963-967.
42. Peipins L.A., Lewin M., Campolucci S., et al. Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA. Environ Health Perspect 2003, 111:1753-1759.
43. Registry AfTSaD. Public health assessment. Libby asbestos site. Libby, Lincoln County, Montana; 2003.
44. Cline R.J., Orom H., Berry-Bobovski L., et al. Community-level social support responses in a slow-motion technological disaster: the case of Libby, Montana. Am J Community Psychol 2010, 46:1-18.
45. Reid A., Berry G., de Klerk N., et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest 2007, 131:376-382.
46. Reid A., Heyworth J., de Klerk N., Musk A.W. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia. Occup Environ Med 2008, 65:743-749.
47. Reid A., Heyworth J., de Klerk N.H., Musk B. Cancer incidence among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia. Int J Cancer 2008, 122:2337-2344.
48. Reid A., Berry G., Heyworth J., de Klerk N.H., Musk A.W. Predicted mortality from malignant mesothelioma among women exposed to blue asbestos at Wittenoom, Western Australia. Occup Environ Med 2009, 66:169-174.
49. Lilienfeld D.E. Asbestos-associated pleural mesothelioma in school teachers: a discussion of four Casesa. Ann N Y Acad Sci 1991, 643:454-458.
50. Omenn G.S., Merchant J., Boatman E., et al. Contribution of environmental fibers to respiratory cancer. Environ Health Perspect 1986, 70:51-56.
51. Anderson H.A., Hanrahan L.P., Higgins D.N., Sarow P.G. A radiographic survey of public school building maintenance and custodial employees. Environ Res 1992, 59:159-166.
52. Cordier S., Lazar P., Brochard P., Bignon J., Ameille J., Proteau J. Epidemiologic investigation of respiratory effects related to environmental exposure to asbestos inside insulated buildings. Arch Environ Health 1987, 42:303-309.
53. Cordier S., Lazar P., Brochard P., Bignon J., Ameille J., Proteau J. Epidemiologic investigation of respiratory effects related to environmental exposure to asbestos inside insulated buildings. Arch Environ Health: Int J 1987, 42:303-309.
54. Olsen N.J., Franklin P.J., Reid A., et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 2011, 195:271-274.
55. Bourdes V., Boffetta P., Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 2000, 16:411-417.
56. Pan X.L., Day H.W., Wang W., Beckett L.A., Schenker M.B. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005, 172:1019-1025.
57. Constantopoulos S.H., Saratzis N.A., Kontogiannis D., Karantanas A., Goudevenos J.A., Katsiotis P. Tremolite whitewashing and pleural calcifications. Chest 1987, 92:709-712.
58. Constantopoulos S.H., Goudevenos J.A., Saratzis N., Langer A.M., Selikoff I.J., Moutsopoulos H.M. Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology. Environ Res 1985, 38:319-331.
59. Sebastien P., Gaudichet A., Bignon J., Baris Y.I. Zeolite bodies in human lungs from Turkey. Lab Invest 1981, 44:420-425.
60. Sakellariou K., Malamou-Mitsi V., Haritou A., et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?. Eur Respir J 1996, 9:1206-1210.
61. Senyigit A., Babayigit C., Gokirmak M., et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000, 67:610-614.
62. Smith D.D. Women and mesothelioma. Chest 2002, 122:1885-1886.
63. Metintas M., Ozdemir N., Hillerdal G., et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999, 93:349-355.
64. Metintas S., Metintas M., Ucgun I., Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002, 122:2224-2229.
65. Metintas M., Hillerdal G., Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J 1999, 13:523-526.
66. NRC. Canadian minerals yearbook 2006 - Chrysotile. Ottawa, Ontario; 2006.
67. WHO Elimination of asbestos related diseases 2006, WHO.
68. AFP Russia protests as global forum urges asbestos ban 2007, AFP.
69. Mossman B., Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998, 157:1666-1680.
70. Bernstein D.M., Chevalier J., Smith P. Comparison of Calidria chrysotile asbestos to pure tremolite: inhalation biopersistence and histopathology following short-term exposure. Inhal Toxicol 2003, 15:1387-1419.
71. Bernstein D.M., Rogers R., Smith P. The biopersistence of Canadian chrysotile asbestos following inhalation. Inhal Toxicol 2003, 15:1247-1274.
72. Bernstein D.M., Rogers R., Smith P. The biopersistence of brazilian chrysotile asbestos following inhalation. Inhal Toxicol 2004, 16:745-761.
73. McDonald J.C., Armstrong B., Case B., et al. Mesothelioma and asbestos fiber type. Evidence from lung tissue analyses. Cancer 1989, 63:1544-1547.
74. Rogers A.J., Leigh J., Berry G., Ferguson D.A., Mulder H.B., Ackad M. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. A case-control study. Cancer 1991, 67:1912-1920.
75. Stanton M.F., Layard M., Tegeris A., et al. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst 1981, 67:965-975.
76. Stanton M.F., Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J Natl Cancer Inst 1972, 48:797-821.
77. Suzuki Y., Yuen S.R., Ashley R. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ Health 2005, 208:201-210.
78. Pezerat H. Chrysotile biopersistence: the misuse of biased studies. Int J Occup Environ Health 2009, 15:102-106.
79. Stayner L.T., Dankovic D.A., Lemen R.A. Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Aust J Public Health 1996, 86:179-186.
80. Rowlands N., Gibbs G.W., McDonald A.D. Asbestos fibres in the lungs of chrysotile miners and millers - a preliminary report. Ann Occup Hyg 1982, 26:411-415.
81. WHO Elimation of asbestos-related diseases 2006.
82. McDonald A.D., Case B.W., Churg A., et al. Mesothelioma in Quebec chrysotile miners and millers: epidemiology and aetiology. Ann Occup Hyg 1997, 41:707-719.
83. Mossman B.T., Bignon J., Corn M., Seaton A., Gee J.B., Asbestos: scientific developments and implications for public policy. Science 1990, 247:294-301.
84. Pooley F.D. An examination of the fibrous mineral content of asbestos lung tissue from the Canadian chrysotile mining industry. Environ Res 1976, 12:281-298.
85. Sebastien P., Janson X., Gaudichet A., Hirsch A., Bignon J. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ 1980, 237-246.
86. Frank A.L., Dodson R.F., Williams M.G. Carcinogenic implications of the lack of tremolite in UICC reference chrysotile. Am J Ind Med 1998, 34:314-317.
87. Mirabelli D., Calisti R., Barone-Adesi F., Fornero E., Merletti F., Magnani C. Excess of mesotheliomas after exposure to chrysotile in Balangero, Italy. Occup Environ Med 2008, 65:815-819.
88. Wang X., Yano E., Qiu H., et al. A 37-year observation of mortality in Chinese chrysotile asbestos workers. Thorax 2012, 67:106-110.
89. Yano E., Wang X., Wang M., Qiu H., Wang Z. Lung cancer mortality from exposure to chrysotile asbestos and smoking: a case-control study within a cohort in China. Occup Environ Med 2010, 67:867-871.
90. Yarborough C.M. Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol 2006, 36:165-187.
91. Hodgson J.T., Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000, 44:565-601.
92. Berman D.W., Crump K.S. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol 2008, 38(Suppl. 1):49-73.
93. McDonald A.D., Fry J.S., Woolley A.J., McDonald J.C. Dust exposure and mortality in an American chrysotile asbestos friction products plant. Br J Ind Med 1984, 41:151-157.
94. Finkelstein M.M., Meisenkothen C. Malignant mesothelioma among employees of a Connecticut factory that manufactured friction materials using chrysotile asbestos. Ann Occup Hyg 2010, 54:692-696.
95. Li L., Sun T.D., Zhang X., et al. Cohort studies on cancer mortality among workers exposed only to chrysotile asbestos: a meta-analysis. Biomed Environ Sci 2004, 17:459-468.
96. Nicholson W.J. The carcinogenicity of chrysotile asbestos - a review. Ind Health 2001, 39:57-64.
97. Nojiri S., Gemba K., Aoe K., et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2010, 41:32-39.
98. Spirtas R., Connelly R.R., Tucker M.A. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988, 41:525-530.
99. Dawson A., Gibbs A.R., Pooley F.D., Griffiths D.M., Hoy J. Malignant mesothelioma in women. Thorax 1993, 48:269-274.
100. Neumann V., Rutten A., Scharmach M., Muller K.M., Fischer M. Factors influencing long-term survival in mesothelioma patients - results of the German mesothelioma register. Int Arch Occup Environ Health 2004, 77:191-199.
101. Hazarika M., White R.M., Booth B.P., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005, 11:982-992.
102. Wolf A.S., Richards W.G., Tilleman T.R., et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 2010, 90:949-956. discussion 56.
103. Pinton G., Brunelli E., Murer B., et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009, 69:4598-4604.
104. Li F.P., Lokich J., Lapey J., Neptune W.B., Wilkins E.W. Familial mesothelioma after intense asbestos exposure at home. JAMA: J Am Med Assoc 1978, 240:467.
105. Hammar S.P., Bockus D., Remington F., Freidman S., LaZerte G. Familial mesothelioma: a report of two families. Hum Pathol 1989, 20:107-112.
106. Heineman E.F., Bernstein L., Stark A.D., Spirtas R. Mesothelioma, asbestos, and reported history of cancer in first-degree relatives. Cancer 1996, 77:549-554.
107. Wagner M.M., Darke C., Coles R.M., Evans C.C. HLA-A and B antigen frequencies and mesothelioma in relation to asbestos exposure. Br J Cancer 1983, 48:727-730.
108. Kukkonen M.K., Hamalainen S., Kaleva S., et al. Genetic susceptibility to asbestos related fibrotic pleuropulmonary changes. Eur Respir J 2010.
109. Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011, 43:1022-1025.
110. Ascoli V., Cavone D., Merler E., et al. Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J Ind Med 2007, 50:357-369.
111. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357:444-445.
112. Dogan A.U., Baris Y.I., Dogan M., et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006, 66:5063-5068.
113. Karakoca Y., Emri S., Bagci T., et al. Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey. Int J Tuberc Lung Dis 1998, 2:1017-1022.
114. Lanphear B.P., Buncher C.R. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992, 34:718-721.
115. Bianchi C., Giarelli L., Grandi G., Brollo A., Ramani L., Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997, 6:162-166.
116. Hilliard A.K., Lovett J.K., McGavin C.R. The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979-1999. Occup Med (Lond) 2003, 53:209-212.
117. Grundy G.W., Miller R.W. Malignant mesothelioma in childhood. Report of 13 cases. Cancer 1972, 30:1216-1218.
118. Fraire A.E., Cooper S., Greenberg S.D., Buffler P., Langston C. Mesothelioma of childhood. Cancer 1988, 62:838-847.
119. Haque A.K., Vrazel D.M., Burau K.D., Cooper S.P., Downs T. Is there transplacental transfer of asbestos? A study of 40 stillborn infants. Pediatr Pathol Lab Med 1996, 16:877-892.
120. Shah K., Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976, 103:1-12.
121. Carbone M., Pass H.I., Rizzo P., et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994, 9:1781-1790.
122. Cristaudo A., Vivaldi A., Sensales G., et al. Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. J Environ Pathol Toxicol Oncol 1995, 14:29-34.
123. Strickler H.D. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 2001, 10:523-532.
124. Bocchetta M., Eliasz S., De Marco M.A., Rudzinski J., Zhang L., Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008, 68:1022-1029.
125. Bocchetta M., Miele L., Pass H.I., Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003, 22:81-89.
126. Foddis R., De Rienzo A., Broccoli D., et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002, 21:1434-1442.
127. Strickler H.D., Goedert J.J., Devesa S.S., Lahey J., Fraumeni J.F., Rosenberg P.S. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 2003, 95:38-45.
128. Kroczynska B., Cutrone R., Bocchetta M., et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A 2006, 103:14128-14133.
129. Terracini B. Additional features of the worldwide double standards in the prevention of asbestos-related diseases. Ann Ist Super Sanita 2006, 42:174-177.
130. Egilman D., Fehnel C., Bohme S.R. Exposing the "Myth" of ABC, "Anything But Chrysotile": a critique of the Canadian asbestos mining industry and McGill University chrysotile studies. Am J Ind Med 2003, 44:540-557.
131. LaDou J., Castleman B., Frank A., et al. The case for a global ban on asbestos. Environ Health Perspect 2010, 118:897-901.